Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

@inproceedings{Funahashi2014EribulinMR,
  title={Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models},
  author={Yasuhiro Funahashi and Kiyoshi Okamoto and Yusuke Adachi and Taro Semba and Mai Uesugi and Yoichi Ozawa and Osamu Tohyama and Taisuke Uehara and Takayuki Kimura and Hideki Watanabe and Makoto Asano and Satoshi Kawano and Xavier Tizon and Paul McCracken and Junji Matsui and Ken Aoshima and Kenichi Nomoto and Yoshiya Oda},
  booktitle={Cancer science},
  year={2014}
}
Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B and an inhibitor of microtubule dynamics. Some tubulin-binding drugs are known to have antivascular (antiangiogenesis or vascular-disrupting) activities that can target abnormal tumor vessels. Using dynamic contrast-enhanced MRI analyses, here we show that eribulin induces remodeling of tumor vasculature through a novel antivascular activity in MX-1 and MDA-MB-231 human breast cancer… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS